News about "chemotherapy "

GSK's Jemperli Receives FDA Priority Review for dMMR/MSI-H Locally Advanced Rectal Cancer

GSK’s Jemperli has received FDA priority review for previously untreated dMMR/MSI-H locally advanced rectal cancer, following positive phase 2 AZUR-1 results.

Chemotherapy | 26/08/2026 | By News Bureau

Roche Canada Completes pCPA Negotiations for Perjeta in Early HER2-Positive Breast Cancer

Roche Canada has completed pCPA negotiations for Perjeta in combination with trastuzumab and chemotherapy for eligible patients with HER2-positive early-stage breast cancer, bringing the treatment closer to potential public reimbursement across Canada.

Chemotherapy | 20/08/2026 | By News Bureau

Diakonos Oncology Phase II Glioblastoma Trial Cleared to Continue After DSMB Safety Review

Independent safety review clears Diakonos Oncology’s Phase II DOC1021 glioblastoma trial to proceed, with no safety concerns identified to date.

Chemotherapy | 18/02/2026 | By News Bureau |  217

First Patient Dosed in Phase III Tropian-Lung17 Trial of Datroway in Advanced NSCLC

The global Phase III study evaluates Datroway versus docetaxel in Trop2 NMR-positive advanced nonsquamous NSCLC patients previously treated with immunotherapy and platinum chemotherapy.

Chemotherapy | 14/01/2026 | By News Bureau |  270

Phanes Therapeutics Presents First Clinical Data for Spevatamig in Metastatic Pancreatic Cancer

Early data from the Twinpeak study presented at ASCO GI 2026 show encouraging safety and efficacy of spevatamig combined with chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma.

Chemotherapy | 12/01/2026 | By News Bureau |  339

Common Cholesterol Drug Shows Promise Against Drug-Resistant Breast Cancer

Korea University researchers show the cholesterol drug inhibits Mcl-1, suppresses metastasis, and restores chemotherapy sensitivity in preclinical models of aggressive TNBC.

Chemotherapy | 08/01/2026 | By News Bureau |  344

China Updates Ivonescimab Label After NSCLC Survival Gains

China’s drug regulator has approved a label update for Akeso’s ivonescimab, citing Phase III data showing significant improvements in progression-free and overall survival in EGFR-TKI-resistant non-small cell lung cancer patients.<br />

Chemotherapy | 07/01/2026 | By News Bureau |  541

Cantargia Secures US Patent for Nadunolimab in Cancer Combination Therapies

Cantargia has announced that the United States Patent and Trademark Office (USPTO) has granted a new patent covering its antibody, nadunolimab.

Chemotherapy | 27/08/2025 | By Dineshwori |  359

Amgen Reports Positive Interim Results for IMDELLTRA in Small Cell Lung Cancer Study

IMDELLTRA demonstrated statistically significant and clinically meaningful improvement in overall survival compared to local standard-of-care chemotherapy.

Chemotherapy | 14/04/2025 | By Abha |  571

Akeso Gets NMPA Approval of Penpulimab for Nasopharyngeal Cancer

With this new approval, penpulimab now provides comprehensive treatment coverage across all stages of NPC, offering patients a continuous immunotherapy option from first-line to third-line therapy.

Chemotherapy | 17/03/2025 | By Aishwarya |  534